| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $24,999,970 | 2 | 6 |
Sells | $608,228 | 29 | 94 |
| ARCH Venture Fund XIII, L.P. | 10 percent owner | 1 | $12.5M | 0 | $0 | $12.5M |
| ARCH Venture Partners IX, LLC | 10 percent owner | 1 | $12.5M | 0 | $0 | $12.5M |
| Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | 0 | $0 | 2 | $274 | $-274 |
| Aguirre Jarrad Mattieu | Chief Medical Officer | 0 | $0 | 1 | $3,642 | $-3,642 |
| Shook David | Chief Medical Officer | 0 | $0 | 2 | $31,339 | $-31,339 |
| Hill Stephen J. | Chief Operating Officer | 0 | $0 | 6 | $51,291 | $-51,291 |
| Lee Gary K. | Chief Scientific Officer | 0 | $0 | 6 | $71,693 | $-71,693 |
| Bulis Veronica Sanchez | VP, Corporate Controller | 0 | $0 | 6 | $96,910 | $-96,910 |
| Seely Lynn | President and CEO | 0 | $0 | 6 | $353,079 | $-353,079 |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy …
Over the last 12 months, insiders at Lyell Immunopharma, Inc. have bought $25M and sold $608,228 worth of Lyell Immunopharma, Inc. stock.
On average, over the past 5 years, insiders at Lyell Immunopharma, Inc. have bought $12.72M and sold $291,357 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ARCH Venture Fund XIII, L.P. (10 percent owner) — $12.5M. ARCH Venture Partners IX, LLC (10 percent owner) — $12.5M.
The last purchase of 488,090 shares for transaction amount of $12.5M was made by ARCH Venture Fund XIII, L.P. (10 percent owner) on 2026‑03‑06.
| 2026-10-12 | Sale | Aguirre Jarrad Mattieu | Chief Medical Officer | 422 0.0019% | $8.63 | $3,642 | +13.66% | |
| 2026-09-10 | Sale | Shook David | Chief Medical Officer | 500 0.0021% | $12.70 | $6,350 | -20.33% | |
| 2026-08-21 | Sale | Seely Lynn | President and CEO | 9,589 0.0411% | $15.54 | $149,013 | -30.65% | |
| 2026-08-21 | Sale | Hill Stephen J. | Chief Operating Officer | 989 0.0042% | $15.54 | $15,369 | -30.65% | |
| 2026-08-21 | Sale | Lee Gary K. | Chief Scientific Officer | 1,457 0.0062% | $15.54 | $22,642 | -30.65% | |
| 2026-08-10 | Sale | Seely Lynn | President and CEO | 390 0.0017% | $14.34 | $5,593 | -23.80% | |
| 2026-08-10 | Sale | Hill Stephen J. | Chief Operating Officer | 89 0.0004% | $14.34 | $1,276 | -23.80% | |
| 2026-08-10 | Sale | Lee Gary K. | Chief Scientific Officer | 131 0.0006% | $14.34 | $1,879 | -23.80% | |
| 2026-08-10 | Sale | Bulis Veronica Sanchez | VP, Corporate Controller | 621 0.0027% | $14.34 | $8,905 | -23.80% | |
| 2026-07-17 | Sale | Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | 10 <0.0001% | $13.70 | $137 | -9.31% | |
| 2026-07-16 | Sale | Innovative Cellular Therapeutics Holdings Ltd | 10 percent owner | 10 <0.0001% | $13.73 | $137 | -12.17% | |
| 2026-06-10 | Sale | Shook David | Chief Medical Officer | 1,977 0.0081% | $12.64 | $24,989 | -2.65% | |
| 2026-05-11 | Sale | Seely Lynn | President and CEO | 388 0.0016% | $18.91 | $7,337 | -32.40% | |
| 2026-05-11 | Sale | Hill Stephen J. | Chief Operating Officer | 89 0.0004% | $18.92 | $1,684 | -32.40% | |
| 2026-05-11 | Sale | Lee Gary K. | Chief Scientific Officer | 130 0.0005% | $18.92 | $2,460 | -32.40% | |
| 2026-05-11 | Sale | Bulis Veronica Sanchez | VP, Corporate Controller | 217 0.0009% | $18.91 | $4,103 | -32.40% | |
| 2026-03-06 | ARCH Venture Partners IX, LLC | 10 percent owner | 488,090 2.6198% | $25.61 | $12.5M | -36.73% | ||
| 2026-03-06 | ARCH Venture Fund XIII, L.P. | 10 percent owner | 488,090 2.6198% | $25.61 | $12.5M | -36.73% | ||
| 2026-02-11 | Sale | Seely Lynn | President and CEO | 7,455 0.0337% | $23.39 | $174,372 | -40.30% | |
| 2026-02-11 | Sale | Hill Stephen J. | Chief Operating Officer | 1,236 0.0056% | $23.39 | $28,910 | -40.30% |
| ARCH Venture Partners IX, LLC | 10 percent owner | 1426528 5.8214% | $15.36M | 1 | 0 | |
| ARCH Venture Fund XIII, L.P. | 10 percent owner | 1426528 5.8214% | $15.36M | 1 | 0 | |
| Seely Lynn | President and CEO | 63899 0.2608% | $688,192.23 | 1 | 9 | +11.7% |
| Klausner Richard | director | 843365 3.4416% | $9.08M | 1 | 1 | +11.7% |
| Ramachandra Sumant | director | 200000 0.8162% | $2.15M | 1 | 0 | +14.09% |
| BRAWLEY OTIS W | director | 35640 0.1454% | $383,842.80 | 1 | 0 | +46.93% |
| FRIEDMAN CATHY | director | 17648 0.072% | $190,068.96 | 1 | 0 | <0.0001% |
| Newton Charles W. | Chief Financial Officer | 15306 0.0625% | $164,845.62 | 1 | 3 | +26.98% |
$60,836,085 | 69 | 0.45% | $255.44M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 33 | +53.23% | 3M | +32.5% |
| Decreased Positions | 21 | -33.87% | 370,412 | -3.73% |
| New Positions | 15 | New | 3M | New |
| Sold Out Positions | 5 | Sold Out | 72,323 | Sold Out |
| Total Postitions | 74 | +19.35% | 13M | +28.77% |
| Arch Venture Management, Llc | $79,958.00 | 13.14% | 2.76M | +938,438 | +51.55% | 2025-09-30 |
| Mwg Management Ltd. | $29,215.00 | 4.8% | 1.01M | 0 | 0% | 2025-09-30 |
| Foresite Capital Management Iv, Llc | $23,196.00 | 3.81% | 800,399 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $22,576.00 | 3.71% | 779,004 | +336,378 | +76% | 2025-09-30 |
| Orland Properties Ltd | $21,871.00 | 3.59% | 754,698 | 0 | 0% | 2025-09-30 |
| Decheng Capital Llc | $17,257.00 | 2.84% | 595,466 | 0 | 0% | 2025-09-30 |
| Almitas Capital Llc | $16,745.00 | 2.75% | 577,807 | -2,190 | -0.38% | 2025-09-30 |
| Foresite Capital Management V, Llc | $13,826.00 | 2.27% | 477,078 | +70,426 | +17.32% | 2025-09-30 |
| Venbio Partners Llc | $13,721.00 | 2.26% | 473,479 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $9,838.00 | 1.62% | 339,491 | +68,208 | +25.14% | 2025-09-30 |